Vitura Health (ASX:VIT) reported that Doctors on Demand exceeded one million cumulative consultations and achieved sustained EBITDA profitability since acquisition. The telehealth result needs to be read alongside the group’s FY26 statutory loss and the performance of its other businesses.

A Multi-Channel Healthcare Access Business

Vitura Health operates across several linked parts of the Australian healthcare access market, combining its Doctors on Demand telehealth service with pharmacy and medicinal cannabis distribution operations. The strategic logic behind the combination is that a telehealth consultation can lead directly into a prescription that Vitura's own distribution channels then fulfil, reducing the number of separate providers a patient needs to deal with, while giving the company Revenue exposure at more than one point in the patient journey.

One Million Consultations and a New Distribution Agreement

Vitura reported more than one million Doctors on Demand consultations and sustained EBITDA profitability for that business. Its FY26 results were released in August 2026 and showed a group statutory loss after tax of A$4.41 million. The telehealth measure and group result cover different scopes and should not be treated as equivalent.

What the Evidence Means

Consultation Volume measures reach, while the reported telehealth EBITDA reflects that business’s Earnings before interest, tax, Depreciation and amortisation. Neither metric alone establishes group profitability. The FY26 accounts provide the group-level context.

Positioning Within Australia's Telehealth and Pharmacy Sector

Vitura sits at the intersection of two sectors that Australian regulators have scrutinised closely in recent years: telehealth prescribing practices, particularly around remote consultations that lead directly to prescription medicines, and medicinal cannabis distribution, which operates under its own specific regulatory framework. Companies that can demonstrate durable profitability while remaining clearly within evolving regulatory guardrails tend to be viewed more favourably by investors than pure consultation-volume growth stories, which is the context in which Vitura's sustained-profitability claim for Doctors on Demand should be assessed.

Risks and What to Watch

Risks include telehealth prescribing rules, medicinal-cannabis distribution conditions, operating costs and integration across businesses. Readers should assess future disclosures for segment performance alongside the group’s statutory results.

Readers should monitor subsequent segment disclosures, group Cash Flow and any contribution from new distribution arrangements. The FY26 financial report has already been released.